根据名称进行药物检索

Paroxetine Suspension 与 Zonalon

Paroxetine Suspension 与 Zonalon互相作用以及同时服用的可能性。

检测结果:

Paroxetine Suspension <> Zonalon

现实性: 13.10.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

谈谈你的医生之前使用多虑平的局部和帕罗西汀。这种结合可能引起镇静作用、口干、视力模糊便秘、或尿潴留。你可能还具有改变的意识、混乱、贫穷肌肉的协调、腹部痉挛、颤抖、瞳孔扩张、出汗、高血压和高心率。如果你采取这两种药物在一起，告诉医生，如果你有任何的这些症状。你可能需要的剂量调整或特别的测试，如果你采取这两种药物。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

一般避免：共同给予与帕罗西汀可能会显着增加的等离子体浓度的一些三环抗抑郁药(机师). 拟议的机制是帕罗西汀的抑制作用CYP450 2D6，同工酶负责的新陈代谢的间隙很多的抗抑郁和精神药物。几倍增加的血浆水平和减少代谢清除已被报告为地昔帕明和郁症，而较小的变化，已有报道对阿米替林和丙咪嗪，大概是因为其他CYP450同功也参与在他们的新陈代谢。 Pharmacodynamically，结合帕罗西汀的(或者任何其他选择性的血清素再吸收抑制剂)和TCA可能会加强风险的血清素综合症，这是一个罕见的，但是严重的和潜在的致命状况的思想导致过度刺激的脑干5HT1A受体。

管理：在一般情况下，使用帕罗西汀的(或其他Ssri)与机师应该可以避免的，如果可能的话，或其谨慎处理，如果潜在的利益被认为大于风险。药物反应和等离子体TCA级别应监测更密切地随时帕罗西汀是加入或撤离治疗的患者中稳定在他们现有的抗抑郁治疗方案，并TCA剂量调整是必要的。患者应密切监测为的迹象和症状的TCA毒性(例如，镇静、口干、视力模糊便秘、尿潴留)和/或过量的血清素的活动(例如，中枢神经系统烦躁不安，改变意识、混乱、肌阵挛、共济失调、腹部痉挛、次高烧、颤抖、瞳孔扩张、发汗解表、高血压、心动过速).

来源

Venkatakrishnan K, Schmider J, Harmatz JS, et al. "Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies." J Clin Pharmacol 41 (2001): 1043-54
Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
Popli AP, Baldessarini RJ, Cole JO "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 51 (1994): 666-7
Riesenman C "Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal." Pharmacotherapy 15 (1995): s84-99
Leucht S, Hackl HJ, Steimer W, Angersbach D, Zimmer R "Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients." Psychopharmacology 147 (2000): 378-83
Laine K, Tybring G, Hartter S, et al. "Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test." Clin Pharmacol Ther 70 (2001): 327-35
Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2
Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT "Cytochromes p450 mediating the n-demethylation of amitriptyline." Br J Clin Pharmacol 43 (1997): 137-44
Vonmoltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI "Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants." J Clin Psychopharmacol 15 (1995): 125-31
Taylor D "Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination - interactions and therapeutic uses." Br J Psychiatry 167 (1995): 575-80
Ereshefsky L, Riesemman C, Lam YW "Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6." Clin Pharmacokinet 29(Suppl 1) (1995): 10-8; discussion 18-9
Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5
Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7
Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2
Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF "Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine." Eur J Clin Pharmacol 44 (1993): 349-55
Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
Yang TJ, Krausz KW, Sai Y, Gonzalez FJ, Gelbon HV "Eight inhibitory monoclonal antibodies define the role of individual P-450S in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism." Drug Metab Dispos 27 (1999): 102-9
Albers LJ, Reist C, Helmeste D, Vu R, Tang SW "Paroxetine shifts imipramine metabolism." Psychiatry Res 59 (1996): 189-96
Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13